title: Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
abstract: OBJECTIVE
  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (HIPEC) can improve survival in selected patients with peritoneal carcinomatosis, but bear a significant risk of perioperative morbidity. The aim of this study was to prospectively evaluate the quality of life (QoL) following cytoreduction and HIPEC.
  
  
  METHODS
  In this study including 40 patients (65% females) with different primary tumors, the EORTC QLQ-C30 questionnaire was applied prior to CS and HIPEC as well as 3, 9, and 18 months postoperatively.
  
  
  RESULTS
  Global health status was not impaired significantly following HIPEC. Scales and symptom scores that deteriorated 3 months postoperatively (p < 0.05), that is, physical, role, and social functions as well as fatigue, pain, dyspnea, insomnia, and diarrhea, all returned to preoperative values within 9 months.
  
  
  CONCLUSIONS
  Following cytoreductive surgery and HIPEC, QoL returns to preoperative levels within 9 months. Selected patients that are likely to benefit oncologically from HIPEC should not be denied this option for fear of reduced postoperative QoL.
authors.affiliation: Department of General, Visceral, Transplantation, Vascular and Thoracic Surgery, Ludwig Maximilians University, Munich, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Albertsmeier
authors.forename: Alexandra
authors.initials: A
authors.lastname: Hauer
authors.forename: Hanno
authors.initials: H
authors.lastname: Niess
authors.forename: Jens
authors.initials: J
authors.lastname: Werner
authors.forename: Christian
authors.initials: C
authors.lastname: Graeb
authors.forename: Martin K
authors.initials: MK
authors.lastname: Angele
mesh_terms: D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015331:Cohort Studies; D003131:Combined Modality Therapy / Q000379:methods; D013505:Digestive System Surgical Procedures / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D011446:Prospective Studies; D011788:Quality of Life; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome